Competitors, page-9

The relevance here is strategy.

RedHill's Phase 2/3 COVID-19 Study of Opaganib completes in March 2021. My previous post was their Phase 2 results. If the COVID-19 results are positive then Opaganib will be approved before the end of the year.

Now the trick here is quite a clever one commonly used by pharma companies. If RedHill gets a positive readout in their prostate cancer trial, they simply apply for a label extension. The question now becomes will they be able to apply for this approval in a way that shuts out Veyonda from being approved for treating late-state prostate cancer. And the answer is yes, there is a way. They may be considered biosimilars and late-stage prostate cancer is an unmet condition after all.

Redhill's prostate cancer trial reads out in 2022, before the DARRT-2 trial. It's a smart strategy. You shouldn't underestimate a company like Redhill Biopharma, if you look at their pipeline for Opaganib it is clear they are directly challenging Noxopharm.